Table 1.
List of clinical trials of HER2 directed peptide vaccines (Clinical trials.gov)
| Vaccine | Adjuvant | Additional intervention | Condition | Study population | Phase | Status | Clinicaltrials.gov Identifier |
|---|---|---|---|---|---|---|---|
| E75 peptide | GM-CSF | Trastuzumab | HER2 positive breast cancer | High risk, HLA-A2 + or HLA-A3 + or HLA-A24 + or HLA-A26 + patients | II | Active, not recruiting | NCT02297698 |
| E75 peptide | GM-CSF | – | Breast cancer | Patients with Low to intermediate HER2 expression and HLA-A2 or HLA-A3 haplotype | III | Completed | NCT01479244 |
| E75 peptide | GM-CSF | – | Ductal breast carcinoma in Situ | Pre or postmenopausal, HLA-A2-positive patients | II | Active, not recruiting | NCT02636582 |
| E75 peptide | GM-CSF | Trastuzumab | Breast cancer | Node-positive or node-negative, HER2 1 + and 2 + and HLA-A2 and HLA-A3 patients | II | Completed | NCT01570036 |
| E75 peptide | GM-SCF | – | Breast cancer | HER2-positive, HLA-A2 and HLA-A2 patients | I/II | Completed | NCT00841399 |
| E75 peptide | GM-SCF | – | Breast cancer | HLA-A2 and HLA-A3 | I/II | Completed | NCT00854789 |
| GP2 peptide | GM-CSF | Trastuzumab | Breast cancer | HER2-positive (IHC3 + or FISH ≥ 2 and HLA-A2 and HLA-A3 patients | I | Completed | NCT03014076 |
| GP2 peptide | GM-CSF | AE37 peptide | Breast cancer | HER2/neu-positive, node-positive, or high-risk node-negative, HLA-A2 patients | II | Unknowna | NCT00524277 |
| 9 peptides from HER2/neu, CEA, CTA | poly-ICLC | HLA-A1, -A2, -A3, or -A31-positive patients with high risk, HER2 expressing cancer | I | Terminated | NCT01532960 | ||
| HER2/neu peptide vaccine | Breast cancer | HER2 (IHC 3 +), stage II/III patients | I | Completed | NCT01632332 | ||
| HER2/neu peptide vaccine | GM-SCF | Rintatolimod | Breast cancer | HER2 (IHC 1 + 2+3 +) stage II, III (A,B,C) and IV breast cancer | I/II | Active, not recruiting | NCT01355393 |
| HER2/neu peptide vaccine | Breast cancer | HER2 (IHC 3 +) HLA-A2-positive, stage IV | II | Terminated | NCT01729884 | ||
| HER2/neu peptide vaccine | GM-CSF | Cyclophosphamide | Breast cancer | HER2 (IHC 2 + or 3 +), stage IV breast cancer | II | Completed | NCT00791037 |
| HER2/neu peptide vaccine MUC-1 peptide vaccine | GM-CSF | CpG oligodeoxynucleotide incomplete Freund’s adjuvant | Breast cancer | HER2-positive, Triple-negative, Muc-1-positive and HLA-A2 patients | Early phase I | Completed | NCT00640861 |
| HER2/neu peptide vaccine | Breast and ovarian cancers | HER2 (IHC 2 + , 3 +), HLA-A2-positive breast or ovarian cancer with stage IV | I/II | Active, not recruiting | NCT00194714 |
aStudy has passed its completion date and status has not been verified in more than 2 years